25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option through the Pharmaceutical Benefits Scheme.

Mylotarg (gemtuzumab ozogamicin) is being listed for the first time for the treatment of patients with previously untreated de novo CD33 positive acute myeloid leukaemia, for use in combination with standard intensive chemotherapy.

Read Minister of Health press release